Show simple item record

dc.contributor.authorSchiavone, F
dc.contributor.authorBathia, R
dc.contributor.authorLetchemanan, K
dc.contributor.authorMasters, L
dc.contributor.authorAmos, C
dc.contributor.authorBara, A
dc.contributor.authorBrown, L
dc.contributor.authorGilson, C
dc.contributor.authorPugh, C
dc.contributor.authorAtako, N
dc.contributor.authorHudson, F
dc.contributor.authorParmar, M
dc.contributor.authorLangley, R
dc.contributor.authorKaplan, RS
dc.contributor.authorParker, C
dc.contributor.authorAttard, G
dc.contributor.authorClarke, NW
dc.contributor.authorGillessen, S
dc.contributor.authorJames, ND
dc.contributor.authorMaughan, T
dc.contributor.authorSydes, MR
dc.contributor.authorpast and present members of the STAMPEDE and FOCUS4 Trial Management Group,
dc.date.accessioned2019-06-24T08:53:35Z
dc.date.issued2019-05-29
dc.identifier.citationTrials, 2019, 20 (1), pp. 264 - ?
dc.identifier.issn1745-6215
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3269
dc.identifier.eissn1745-6215
dc.identifier.doi10.1186/s13063-019-3216-8
dc.description.abstractBACKGROUND: There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons when compelling clinical and scientific research questions emerge, and (2) early stopping of accrual to individual comparisons that do not show sufficient activity without affecting other active comparisons. Adaptive platform design trials also offer many potential benefits over traditional trials, from faster time to accrual to contemporaneously recruiting multiple research comparisons, added flexibility to focus on more promising research comparisons via pre-planned interim analyses and potentially shorter time to primary results. We share here our experiences from a trial management perspective, highlighting the challenges and successes. METHODS: We evaluated the operational aspects of making changes to these adaptive platform trials and identified both common and trial-specific challenges. The operational steps and challenges linked to both the addition of new research comparisons and stopping recruitment following pre-planned interim analysis were considered in our evaluation. RESULTS: Specific operational challenges in these adaptive platform protocols, additional to those in traditional two-arm trials, were identified. Key lessons are presented describing some of the solutions and considerations over conducting these trials. Careful consideration on the practicality of the protocol structure (modular versus single protocol), the longevity and continuity of trial oversight committees, and having clear clinical and scientific criteria for the addition of new research comparisons were identified as some of the most common challenges. CONCLUSIONS: Understanding the operational complexities associated with running adaptive platform protocols is paramount for their conduct, adaptive platform trials offer an efficient model to run randomised controlled trials and we are continuing to work to reduce further the effort required from an operational perspective. TRIAL REGISTRATION: FOCUS4: ISRCTN Registry, ISRCTN90061546 . Registered on 16 October 2013. STAMPEDE: ISRCTN Registry, ISRCTN78818544 . Registered on 2 February 2004.
dc.formatElectronic
dc.format.extent264 - ?
dc.languageeng
dc.language.isoeng
dc.publisherBMC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectpast and present members of the STAMPEDE and FOCUS4 Trial Management Group
dc.subjectHumans
dc.subjectClinical Protocols
dc.subjectLeadership
dc.subjectPeer Review
dc.subjectResearch Design
dc.subjectClinical Trials as Topic
dc.titleThis is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
dc.typeJournal Article
dcterms.dateAccepted2019-01-19
rioxxterms.versionofrecord10.1186/s13063-019-3216-8
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-05-29
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfTrials
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume20
pubs.embargo.termsNot known
icr.researchteamProstate and Bladder Cancer Research
dc.contributor.icrauthorJames, Nicholas


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0